New analysis shows lebrikizumab helps clear skin faster than placebo for atopic dermatitis

People with moderate-to-severe atopic dermatitis often struggle to find treatments that truly clear their skin. A new look at two large Phase 3 trials offers fresh hope. The analysis involved 564 adults and adolescents who took lebrikizumab and 287 who took a placebo. Researchers tracked how well the skin cleared over 16 weeks and again at 52 weeks. They found that significantly more patients on lebrikizumab achieved clear skin compared to those on the placebo. This means the drug works better at removing the redness and itch that define this condition. The study also looked at how long the benefits lasted. High rates of lasting skin clearing were seen in the treatment group. For those who did not respond well, skin scores remained low and stable. For those who did not respond, scores were reduced. This analysis helps doctors understand what patients can expect from this specific medication.